Micro-Series | Part 4 | DLL3 in EP-NEC: A New Therapeutic Target Comes Into Focus

Take a closer look at DLL3 as an emerging biomarker and therapeutic target in EP‑NEC. Dr. Pelster discusses the biology behind DLL3 overexpression and the latest clinical data on DLL3‑directed therapies, including bispecific T‑cell engagers. This episode is part of the Micro-Series, EP-NEC Explained: Diagnosis to Emerging Therapies. Developed and produced by Ontada Learn. The content is intended for educational purposes and reflects current research and expert opinion as of the release date.